AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well AZD2171 works in treating patients with recurrent or
stage IV melanoma. AZD2171 may stop the growth of tumor cells by blocking blood flow to the
tumor and by blocking some of the enzymes needed for cell growth.